P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

Duane S. Pinto; Hector Tamez; Serge Korjian; Yazan Daaboul; Roxana Mehran; Christoph Bode; Jonathan L. Halperin; Freek W.A. Verheugt; Peter Wildgoose; Martin van Eickels; Professor Gregory Lip; Marc Cohen; Eric D. Peterson; Keith A.A. Fox; C. Michael Gibson

doi:10.1093/eurheartj/ehx504.p4569

Shared by

Professor Gregory Lip

University of Liverpool

P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

Article 2017 en

Authors

DP
Duane S. Pinto
HT
Hector Tamez
SK
Serge Korjian

Abstract

1 min read

Bleeding and LAA occlusion / Risk prediction 965 Spontaneous (n=358) Traumatic (n=234) p Age, median [IQR] 78 [72-84] 81 [74-86] <0.01 Female 151 (42%) 96 (41%) 0.78 CHA2DS2-VASc, median [IQR] 4 [3-5] 4 [3-5] 0.076 HAS-BLED >3 130 (36%) 98 (42%) 0.17 INR >3 115 (33%) 78 (35%) 0.85 Antiplatelet drug 62 (18%) 36 (16%) 0.55 Intracerebral haemorrhage 268 (67%) 38 (17%) Subdural hematoma 89 (25%) 150 (67%) Subarachnoid heamorrhage 19 (5%) 6 (3%) Multiple anatomic locations 11 (3%) 31 (14%) 30-day mortality 125 (36%) 55 (25%) <0.01 AF = atrial fibrillation; IQR = interquartile range.

Related publications

Article2017

P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

Megan K. Yee, Gerald Chi, Parvesh Kumar Jain, R. Mehran, C. Bode, J. Halperin, F.W.A. Verheugt, Peter Wildgoose, Serge Korjian, Yazan Daaboul, Professor Gregory Lip, Mark A. Cohen, E. Peterson, Kayleen Fox, C. Michael Gibson

Article2025

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Paula Rodríguez‐Otero, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Salomon Manier, Carmen Martínez‐Chamorro, Rajshekhar Chakraborty, Sam Rubinstein, Anna Sureda, Marta Sonia González, Jean‐Marie Michot, Aurora Breazna, James Drew, Anita Boyapati, Sheila Masinde, Glenn S. Kroog, Shawn Sarkaria, Joaquín Martínez‐López

Article2025

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.

Morten Salomo, Enrique M. Ocio, Carmen Martínez‐Chamorro, Sosana Delimpasi, Albert Oriol, Meletios A Dimopoulos, Xavier P. Leleu, Sam Rubinstein, Nisha S. Joseph, Mercedes Gironella, Rajshekhar Chakraborty, Carlos Fernández de Larrea, Aurora Breazna, James Drew, Anita Boyapati, Anasuya Hazra, Glenn S. Kroog, Shawn Sarkaria, Paula Rodríguez‐Otero

Article2022

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL

Lisa Leypoldt, Maria Gavriatopoulou, Britta Besemer, H. Salwender, Marc‐Steffen Raab, Axel Nogai, Cyrus Khandanpour, V. Runde, Manola Zago, Peter Martus, H. Goldschmidt, Carsten Bokemeyer, Meletios A Dimopoulos, Katja Weisel

Article2014

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results

Meletios A Dimopoulos, Matthew C. Cheung, Murielle Roussel, Ting Liu, Barbara Gamberi, Brigitte Kolb, Hans Guenter Derigs, Hyeon Seok Eom, Karim Belhadj, Pascal Lenain, Richard H. van der Jagt, Sophie Rigaudeau, Mamoun Dib, R. Hall, Arnaud Jaccard, Axel Tosikyan, Lionel Karlin, William Bensinger, Rik Schots, Guang Chen, Jennifer Marek,

P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

Abstract

Discussion(0)

Related publications

P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial.

Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial.

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL

Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results